idarubicin has been researched along with decitabine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Archimbaud, E; Muus, P; Willemze, R | 1 |
| Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Hu, C; Jin, J; Li, K; Mei, C; Ren, Z; Tong, H; Vera, JC; Zhuang, Z | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Guo, X; Zhang, X | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| He, J; Wang, L; Yan, X | 1 |
3 review(s) available for idarubicin and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
2 trial(s) available for idarubicin and decitabine
| Article | Year |
|---|---|
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Time Factors | 1997 |
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |
11 other study(ies) available for idarubicin and decitabine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Nucleus; Cell Proliferation; Decitabine; Down-Regulation; Drug Synergism; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia; Methylation; Mice; Mice, Inbred NOD; Mice, SCID; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; U937 Cells; Wnt Proteins | 2014 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |